Binding domain or antibody specific to a human serum albumin (HSA)
The present disclosure relates to a method of modulating the half-life of a binding domain specific to a serum carrier protein by mutating the sequence and a modulated binding domain specific to a serum carrier protein.
1. A binding domain comprising a variable heavy (VH) domain and variable light (VL) domain specific to a serum carrier protein, wherein the VH and VL sequences are selected from combinations of SEQ ID NOs: 3 and 9, SEQ ID NOs: 4 and 8, SEQ ID NOs: 4 and 9, and SEQ ID NOs: 5 and 9.
2. The binding domain according to claim 1 , wherein the serum carrier protein is human serum albumin.
3. The binding domain according to claim 2 , wherein the binding domain binds to domain II of human serum albumin.
4. The binding domain according to claim 1 , wherein the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 3, respectively.
5. The binding domain according to claim 1 , wherein the VL and VH sequences are SEQ ID NO: 8 and SEQ ID NO: 4 respectively.
6. The binding domain according to claim 1 , wherein the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 5 respectively.
7. The binding domain according to claim 1 , wherein the VL and VH sequences are SEQ ID NO: 9 and SEQ ID NO: 4 respectively.
8. The binding domain according to claim 1 , wherein the binding domain is humanized.
9. The binding domain according to claim 8 , wherein the humanized binding domain comprises a human IgG framework in the VH and/or VL.
10. A pharmaceutical composition comprising the binding domain according to claim 1 .
11. An antibody molecule comprising the binding domain according to claim 1 .
12. A pharmaceutical composition comprising the antibody molecule according to claim 11 .